C4 Therapeutics Inc [CCCC] stock prices are up 8.59% to $4.55 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CCCC shares have gain 12.35% over the last week, with a monthly amount drifted -22.88%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
C4 Therapeutics Inc [NASDAQ: CCCC] stock has seen the most recent analyst activity on November 18, 2024, when Stephens initiated its Equal-Weight rating and assigned the stock a price target of $4. Previously, JP Morgan upgraded its rating to Neutral on January 29, 2024, and kept the price target unchanged to $6. On December 13, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $12 on the stock. Credit Suisse upgraded its rating to a Neutral and decreased its price target to $10 on February 24, 2023. JP Morgan downgraded its rating to a Underweight and reduced its price target to $5 on February 24, 2023. JP Morgan downgraded its rating to Neutral for this stock on November 04, 2022, and downed its price target to $15. In a note dated October 11, 2022, Morgan Stanley initiated an Underweight rating and provided a target price of $6 on this stock.
The stock price of C4 Therapeutics Inc [CCCC] has been fluctuating between $1.06 and $11.88 over the past year. Currently, Wall Street analysts expect the stock to reach $13.5 within the next 12 months. C4 Therapeutics Inc [NASDAQ: CCCC] shares were valued at $4.55 at the most recent close of the market. An investor can expect a potential return of 196.7% based on the average CCCC price forecast.
Analyzing the CCCC fundamentals
The C4 Therapeutics Inc [NASDAQ:CCCC] reported sales of 33.67M for trailing twelve months, representing a surge of 38.75%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -3.54%, Pretax Profit Margin comes in at -3.13%, and Net Profit Margin reading is -3.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.42 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.30 points at the first support level, and at 4.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.72, and for the 2nd resistance point, it is at 4.90.
Ratios To Look Out For
It’s worth pointing out that C4 Therapeutics Inc [NASDAQ:CCCC]’s Current Ratio is 6.31. Further, the Quick Ratio stands at 6.31, while the Cash Ratio is 1.38. Considering the valuation of this stock, the price to sales ratio is 10.36, the price to book ratio is 1.32.
Transactions by insiders
Recent insider trading involved Salter Malcolm, Director, that happened on Nov 18 ’24 when 13000.0 shares were purchased. Director, Salter Malcolm completed a deal on Oct 18 ’24 to buy 13000.0 shares. Meanwhile, Director Salter Malcolm bought 8561.0 shares on Oct 11 ’24.
